Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-20 of 20 for your search:
Drug:
isotretinoin
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma
Phase:
Phase IV, Phase III
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
GPOH-NB2004
, EU-20661, NCT00410631
2.
Phase III Randomized Study of Adjuvant Isotretinoin With or Without Monoclonal Antibody Ch14.18, Interleukin-2, and Sargramostim (GM-CSF) in Patients With Neuroblastoma Who Have Completed Myeloablative Therapy and Autologous Stem Cell Transplantation
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
30 and under at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-ANBL0032
, ANBL0032, COG-P9842, NCT00026312
3.
Phase III Randomized Study of Induction Chemotherapy With or Without Filgrastim (G-CSF) Followed By Surgery, Myeloablative Therapy, and Radiotherapy With Isotretinoin With or Without Monoclonal Antibody Ch14.18 in Patients With High-Risk Neuroblastoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
1 to 20 at diagnosis
Sponsor:
Other
Protocol IDs:
SIOP-EUROPE-HR-NBL-1
, ESIOP, EU-20148, NCT00030719
4.
Phase III Randomized Study of Standard Chemoradiotherapy With or Without Carboplatin Followed by Standard Maintenance Therapy With or Without Isotretinoin and Continuation Therapy With Isotretinoin Versus No Continuation Therapy in Pediatric Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
3 to 21
Sponsor:
NCI
Protocol IDs:
COG-ACNS0332
, ACNS0332, NCT00392327
5.
Phase III Study of Response- and Biology-Based Combination Chemotherapy and Surgery With or Without Isotretinoin in Young Patients With Intermediate-Risk Neuroblastoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
12 and under
Sponsor:
NCI
Protocol IDs:
COG-ANBL0531
, ANBL0531, NCT00499616
6.
Phase III Randomized Study of Single Versus Tandem Myeloablative Consolidation Therapy Followed by Peripheral Blood Stem Cell Transplantation in Young Patients With High-Risk Neuroblastoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
30 and under
Sponsor:
NCI
Protocol IDs:
COG-ANBL0532
, ANBL0532, NCT00567567
7.
Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-Cis-Retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
EPO2006-AISSM04
, 2006-006482-16, NCT00804050
8.
Phase I/II Study of Vorinostat (SAHA) in Combination With Isotretinoin in Patients With Advanced Renal Cell Carcinoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
21 and over
Sponsor:
NCI
Protocol IDs:
NYWCCC-0511008257
, 6896, NCI-6896, NCT00324740
9.
Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-0709
, NCT00555399
10.
Phase I/II Study of Cytoreduction Therapy Comprising High-Dose Cytarabine and Mitoxantrone Hydrochloride in Patients With Juvenile Myelomonocytic Leukemia Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Residual Disease
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Juvenile
Sponsor:
NCI
Protocol IDs:
UMN-1999LS032
, UMN-1999LS032, UMN-MT1999-08, NCT00609739
11.
A Phase I/Ii Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells After High-Dose Chemotherapy And Autologous Stem Cell Rescue In Patients With High Risk Neuroblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 21
Sponsor:
Other
Protocol IDs:
22053
, NCT00703222
12.
Phase II Randomized Study of Adjuvant Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Patients Who Have Undergone Radiotherapy for Supratentorial Glioblastoma Multiforme
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MDA-ID-02586
, 2004-0662, 6636, NCI-6636, MDA-2004-0662, NCT00112502
13.
Phase II Study of Isotretinoin, Interferon alfa-2b, and Paclitaxel in Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
CINJ-100101
, NJ 1703, CINJ-3390, CINJ-NJ1703, NCT00138151
14.
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
05-079
, NCT00200161
15.
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 21 years
Sponsor:
Other
Protocol IDs:
NYU 05-40 H12853
, PBMTC ONC-032P, NCT00528437
16.
Phase II Study of Protracted Oral Etoposide and Cisplatin During Induction Therapy in Pediatric Patients With Previously Untreated High-Risk Neuroblastoma Undergoing High-Dose Chemotherapy and Stem Cell Rescue Followed by Maintenance Therapy Comprising Isotretinoin
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 18
Sponsor:
Other
Protocol IDs:
BCM-H-20225
, 20255, NCT00600132
17.
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 18
Sponsor:
Other
Protocol IDs:
NB2008
, NCT00808899
18.
Phase I Study of PXD101 and Isotretinoin in Patients With Metastatic or Unresectable Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CCC-PHI-53
, 7251, NCI-7251, NCT00334789
19.
Randomized Study of Standard Induction Chemotherapy Versus Topotecan Hydrochloride-Containing Induction Chemotherapy Followed by Myeloablative Autologous Stem Cell Transplantation and Consolidation Therapy With Isotretinoin in Pediatric Patients With High-Risk Neuroblastoma
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
6 months to 21
Sponsor:
Other
Protocol IDs:
GPOH-NB2004-HR
, NB2004-HR, UNI-KOELN-161, NCT00526318
20.
Study of Vorinostat (SAHA), Isotretinoin, and Combination Chemotherapy in Pediatric Patients Who Have Undergone Surgery for Embryonal Tumors of the Central Nervous System
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 months to 3 years
Sponsor:
NCI
Protocol IDs:
PBTC-026
, PBTC-026, PBTC-026, NCT00867178
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
